KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.

Elisabeth De Greef, Dan Turner, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Stanley A Cohen, Jeffrey S Hyams, Anne M Griffiths, Joel R Rosh, Richard Strauss, Els Van Limbergen, Omoniyi J Adedokun, Lilianne Kim, Sheri Volger, UNITI Jr study Group

J Crohns Colitis 20(3) jjag011

PMID41843763
PMCIDPMC13017028
DOI10.1093/ecco-jcc/jjag011
发表日期2026-03-17
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:图注未提示 KM 曲线;Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线;Figure 3.:图注未提示 KM 曲线;Figure 4.:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND: UNITI Jr is a phase 3 study evaluating the efficacy, safety, and pharmacokinetics of ustekinumab, an interleukin-12/-23 antagonist, in pediatric patients with moderately to severely active Crohn's disease. Results from patients weighing at least 40 kg are reported. METHODS: Patients at least 40 kg and aged less than 18 years with a Pediatric Crohn's Disease Activity Index score of >30 received a single intravenous weight-tiered induction dose of ustekinumab. After 8 weeks, patients were randomized to subcutaneous ustekinumab 90 mg every 8 or 12 weeks. The primary endpoint was clinical remission at Week 8. Secondary endpoints included clinical response (Weeks 8, 52), endoscopic response (Weeks 16, 52), clinical remission, and corticosteroid-free remission (Week 52). RESULTS: Of 48 patients, median age was 15.0 years (interquartile range: 14.0-16.0). At Week 8, 52.1% (25/48) achieved clinical remission and 93.8% (45/48) achieved clinical response. At Week 16, 29.8% (14/47) achieved endoscopic response. Clinical remission at Week 52 was achieved in 15/25 (60.0%; every 12 weeks) and 10/23 (43.5%; every 8 weeks). Three patients (6.3%) discontinued ustekinumab between Weeks 8 and 52. Ustekinumab was safe and well-tolerated; adverse event rates were similar between groups. Immunogenicity was low; trough median (mean) steady-state serum ustekinumab concentrations following 8 weeks of dosing were 1.38 (2.08) to 1.74 (2.32) μg/mL and were comparable to levels in adult patients: 2.83 (2.05) μg/mL. CONCLUSIONS: Ustekinumab induction and maintenance therapy was effective and safe through 52 weeks in pediatric patients weighing at least 40 kg with moderately to severely active Crohn's disease. TRIAL REGISTRATION NUMBERS: NCT04673357.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical Abstract无图注
非 KM Figure
Figure 1.Patient disposition. AE, adverse event; CD, Crohn’s disease; LOR, loss of response; LTE, long-term extension; q4w, every 4 weeks; q8w, every 8 weeks; q12w, every 12 weeks; UST, ustekinumab.
非 KM Figure
Figure 2.Clinical remission (primary endpoint) and clinical response at Week 8. Note: outcomes in adult patients were obtained from the UNITI trial. 13 CDAI, Crohn’s Disease Activity Index; CI, confidence interval; PCDAI, Pediatric Crohn’s Disease Activity Index.
非 KM Figure
Figure 3.Comparison of endoscopic response in pediatric and adult CD patients. Note: outcomes in adult patients were obtained from a substudy of the UNITI/IM-UNITI trials. 19 CI, confidence interval; SES-CD, Simple Endoscopic Score for Crohn’s Disease.
非 KM Figure
Figure 4.Clinical outcomes at Week 52 by treatment group. CI, confidence interval; PCDAI, Pediatric Crohn’s Disease Activity Index; q8w, every 8 weeks; q12w, every 12 weeks; SC, subcutaneous.
非 KM Figure